EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bone Growth Induction in Mucopolysaccharidosis IVA Mouse

Estera Rintz iD, Angélica María Herreño-Pachón, Betul Celik iD, Fnu Nidhi, Shaukat Khan, Eliana Benincore-Flórez, Shunji Tomatsu iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24129890 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Estera Rintz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nemours Children's Health, Wilmington, DE 19803, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis IV. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, National Institute of Health, Austrian MPS society, A Cure for Robert, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is caused by a deficiency of the N-acetylgalactosamine-6-sulfate-sulfatase (GALNS) enzyme, leading to the accumulation of glycosaminoglycans (GAG), keratan sulfate (KS) and chondroitin-6-sulfate (C6S), mainly in cartilage and bone. This lysosomal storage disorder (LSD) is characterized by severe systemic skeletal dysplasia. To this date, none of the treatment options for the MPS IVA patients correct bone pathology. Enzyme replacement therapy with elosulfase alpha provides a limited impact on bone growth and skeletal lesions in MPS IVA patients. To improve bone pathology, we propose a novel gene therapy with a small peptide as a growth-promoting agent for MPS IVA. A small molecule in this peptide family has been found to exert biological actions over the cardiovascular system. This work shows that an AAV vector expressing a C-type natriuretic (CNP) peptide induces bone growth in the MPS IVA mouse model. Histopathological analysis showed the induction of chondrocyte proliferation. CNP peptide also changed the pattern of GAG levels in bone and liver. These results suggest the potential for CNP peptide to be used as a treatment in MPS IVA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IVAnimalsMiceKeratan SulfateGlycosaminoglycansCartilageBone Development

Stichwörter der Autor:innen

AAV gene therapyC-type natriuretic peptideMorquio A syndromeossification

Substanzen

Keratan SulfateGlycosaminoglycans

Autor:innen und Institutionen

  • Nemours Children's Health, Wilmington, DE 19803, USA.
  • Department of Molecular Biology, Faculty of Biology, University of Gdansk, 80-308 Gdansk, Poland.
  • Faculty of Arts and Sciences, University of Delaware, Newark, DE 19716, USA.
  • Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19144, USA.

ORCID-Profile: Estera Rintz, Betul Celik, Shunji Tomatsu

Förderung

  • NICHD NIH HHS
  • National Institute of Health
  • Austrian MPS society, A Cure for Robert, Inc.
  • Carol Ann Foundation
  • Angelo R. Cali & Mary V. Cali Family Foundation, Inc.
  • Vain and Harry Fish Foundation, Inc.
  • Bennett Foundation
  • Jacob Randall Foundation

Zitieren

APA

Rintz, E., Herreño-Pachón, A. M., Celik, B., Nidhi, F., Khan, S., Benincore-Flórez, E., & Tomatsu, S. (2023). Bone Growth Induction in Mucopolysaccharidosis IVA Mouse. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24129890

Vancouver

Rintz E, Herreño-Pachón AM, Celik B, Nidhi F, Khan S, Benincore-Flórez E, et al. Bone Growth Induction in Mucopolysaccharidosis IVA Mouse. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24129890

BibTeX
@article{Rintz2023,
  author = {Rintz, Estera and Herreño-Pachón, Angélica María and Celik, Betul and Nidhi, Fnu and Khan, Shaukat and Benincore-Flórez, Eliana and Tomatsu, Shunji},
  title = {Bone Growth Induction in Mucopolysaccharidosis IVA Mouse},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24129890}
}
Kostenlos starten →